Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Rajesh K
RK
Sharma
Sankarathi
S
Balaiya
Kakarla V
KV
Chalam
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis; D000068258:Bevacizumab; D053148:Caspase 3 / Q000378:metabolism; D049109:Cell Proliferation; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014604:Uveal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019394:Ki-67 Antigen; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D053148:Caspase 3